Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Becton Dickinson Raises FY22 Guidance As Q2 Earnings Top Estimates

  • Becton Dickinson and Co (NYSE:BDXreported Q2 FY22 revenues of $5.01 billion, up 2.1% Y/Y (3.9% on a currency-neutral basis), better than the consensus of $4.85 billion.
  • Revenue was driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by the decline in COVID-only testing revenues to $214 million from $474 million in the prior year.
  • Medical segment sales increased 4.5% Y/Y to $2.42 billion.
  • Life Sciences segment sales declined 6.4% Y/Y to $1.48 billion, reflecting the decline in COVID-only testing revenues.
  • Interventional segment revenues grew 9.9% Y/Y to $1.11 billion, reflecting a continued recovery in elective volumes.
  • Operating income increased 50.1% Y/Y to $652 million.
  • Adjusted EPS of $3.18, down from $3.19 a year ago, topping the consensus of $2.99.
  • Guidance: BD expects FY22 sales of $19.6 billion - $19.8 billion, compared to earlier guidance of $19.55 billion - $19.75 billion, versus the consensus of $19.63 billion.
  • Becton Dickinson reaffirms approximately $450 million in COVID-19-only diagnostic testing revenues.
  • It anticipates FY22 adjusted EPS of $12.85 - $13, up from prior guidance of $12.80 - $13.00 versus the consensus of $12.85.
  • Price Action: BDX shares are up 1.06% at $256.22 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.